Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go ...

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Trying to get in more protein at breakfast? Eggs are a great start. It's pretty typical to use two eggs as the basis for breakfast, whether you're serving them scrambled, hard-boiled or over easy.

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis ...

Biogen has ducked out of a four-year-old collaboration ... It inhibits the nuclear export protein exportin-1 (XPO1), the same target as Karyopharm's approved cancer therapy Xpovio (selinexor ...

Researchers from Auburn University, partnering with the University of Basel in Switzerland, have discovered a new way to make ...

When you think about the benefits of protein, building and maintaining muscle are likely what come to mind. But this powerhouse nutrient has many other benefits as well—from increasing energy ...

Biogen is making a few changes to its C-suite. The drugmaker will bring on Bristol Myers Squibb exec Daniel Quirk as chief medical officer and head of medical affairs, a move announced one day after ...

The highly anticipated second season of “The Night Agent” has set its premiere date at Netflix. Season 2 of the action thriller series will drop in its entirety on Jan. 23, 2025 on the ...

Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. But to truly unlock the amyloid-busting antibody’s potential, the company will ...

Biotechnology firm Biogen Inc (NASDAQ:BIIB) is scheduled to report third-quarter results before the open on Wednesday, Oct. 30. Ahead of the event, it was announced that Biogen's Executive V.P ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. After a rejection in July, drug reviewers at the EMA have now ...